2 Space Stocks to Buy in July (Hint: Not SpaceX)

The article highlights SpaceX’s record-setting IPO (raised nearly $86B) and warns its post-IPO period may be volatile due to a staggered lockup and an extreme valuation (P/S ~115). In contrast, Rocket Lab is up more than 50% in 2026 and announced an agreement to acquire Iridium Communications to build an integrated launch-to-satellite network (P/S ~85.5), while Redwire is up 65% in 2026 and saw defense revenue jump to $44.3M vs $9.2M prior year, driving a 58% quarterly revenue gain largely from defense. Overall, it argues Rocket Lab and Redwire may offer space and defense growth exposure with less valuation risk than SpaceX.

Analysis

The market is likely overpaying for the “space beta” label and underpricing the dispersion inside the basket. In the next few days, flow will probably favor the highest beta names, but over 1-3 months the real separator is balance-sheet optionality: companies needing dilution or acquisition financing will underperform once the narrative trades back to cash burn and integration risk. The best setup is not a blanket long space trade; it is a relative-value trade between story-rich, expensive names and cheaper defense-adjacent operators with actual program content.

The lockup overhang in the newly public name creates a natural supply wall, so any strength there is likely to fade as secondary sellers surface and implied volatility stays elevated. By contrast, names with direct exposure to defense procurement and mission-critical subsystems can benefit from budget durability, but that upside usually accrues slowly as contract vehicles convert into revenue—months, not weeks. The key second-order effect is that the strongest near-term beneficiary may be not the launch provider but the firms selling picks-and-shovels into orbital surveillance, testing, and autonomy.

Contrarian take: the crowd is treating space as if it were an AI-like secular rerating, when in reality most of the economics are still lumpy, government-reliant, and capex intensive. That means multiples can compress hard if any one catalyst slips—a launch delay, delayed integration benefits, or a financing overhang. The thesis is falsified if the expensive names can convert enthusiasm into sustained upward revisions in gross margin and free cash flow over the next two quarters; absent that, the move is likely more sentiment than fundamentals.

Key Decisions for Investors

• Short SPCX / avoid chasing the post-IPO float: use any strength in the next 2-6 weeks to fade the lockup overhang. Risk/reward improves if borrow is available and implied volatility remains elevated; thesis breaks if the stock holds above its post-lockup range on heavy institutional volume.
• Pair long RDW / short RKLB over 1-3 months: RDW has a cleaner path to monetizing defense spend, while RKLB still trades like an acquisition-and-launch story that needs flawless execution. Falsify the pair if RKLB shows accelerating gross margin and confirms financing terms without dilution.
• If you need long exposure, prefer RDW over the higher-multiple space names for a 6-18 month hold. The valuation gives you more room for program delays and better downside protection; exit if revenue growth decelerates for two consecutive quarters.
• Watch IRDM as a potential source of event-driven mispricing, but do not take a directional position until financing, regulatory, and integration terms are known. If a deal spread opens wider than peers, that may be the cleaner trade than the operating names.